Details for Patent: 10,927,129
Which drugs does patent 10,927,129 protect, and when does it expire?
Patent 10,927,129 protects APRETUDE, CABENUVA KIT, and VOCABRIA, and is included in three NDAs.
This patent has one hundred and twenty-six patent family members in thirty-three countries.
Summary for Patent: 10,927,129
| Title: | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
| Abstract: | The present invention is directed to N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide of the formula: or a pharmaceutically acceptable salt or stereoisomer thereof, and pharmaceutical compositions comprising the same. The present invention has HIV integrase inhibitory activity. |
| Inventor(s): | Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda |
| Assignee: | Shionogi and Co Ltd , ViiV Healthcare Co |
| Application Number: | US16/400,373 |
|
Patent Claim Types: see list of patent claims | Composition; |
Drugs Protected by US Patent 10,927,129
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | APRETUDE | cabotegravir | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 215499-001 | Dec 20, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-001 | Jan 21, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-002 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,927,129
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2005-131161 | Apr 28, 2005 |
| Japan | 2005-312076 | Oct 27, 2005 |
International Family Members for US Patent 10,927,129
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1874117 | ⤷ Start Trial | C300676 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1874117 | ⤷ Start Trial | CA 2014 00032 | Denmark | ⤷ Start Trial |
| European Patent Office | 1874117 | ⤷ Start Trial | PA2014021 | Lithuania | ⤷ Start Trial |
| European Patent Office | 1874117 | ⤷ Start Trial | 1490036-9 | Sweden | ⤷ Start Trial |
| European Patent Office | 1874117 | ⤷ Start Trial | C20140020 00130 | Estonia | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
